Items Tagged ‘PD1’

April 19th, 2017

Combination Immunotherapy with Yervoy and Opdivo Improves Overall Survival Compared to Yervoy Alone in Patients with Previously Untreated Advanced Melanoma

By

The first overall survival data from the CheckMate -067 clinical trial evaluating Yervoy (ipilumamab) and Opdivo (nivolumab) combinations has just been reported.  The two-year survival rates were 64% for the Opdivo plus Yervoy combination, 59% for Opdivo alone and 45% for Yervoy alone. About Opdivo Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is […]

View full entry

Tags: immunotherapy, Melanoma, News, opdivo, PD1